<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34269426</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1552-4604</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>61</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical pharmacology</Title>
          <ISOAbbreviation>J Clin Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder.</ArticleTitle>
        <Pagination>
          <StartPage>1626</StartPage>
          <EndPage>1637</EndPage>
          <MedlinePgn>1626-1637</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jcph.1940</ELocationID>
        <Abstract>
          <AbstractText>Viloxazine extended-release capsules (viloxazine ER; Qelbree) is a novel nonstimulant, recently approved by the US Food and Drug Administration for the treatment of ADHD in pediatrics. Here, we characterize the pharmacokinetics (PK) of viloxazine and its major metabolite, 5-HVLX-gluc, using a population PK model and evaluate the impact of 1-4 days of missed viloxazine ER doses on viloxazine PK. Data from 4 phase 3 trials in pediatric subjects treated with viloxazine ER were used to establish the PK model. Covariate analysis was conducted on the final base model. The impact of 1-4 days of missed doses on steady-state viloxazine PK was evaluated using Monte Carlo simulations. A 1-compartmental linear model with first-order absorption and elimination of the parent drug and first-order metabolite formation and elimination properly described the population PK of viloxazine and 5-HVLX-gluc. Body weight impacted the systemic exposure of viloxazine and 5-HVLX-gluc. Predicted PK parameters at steady state (mean ± standard deviation) in children receiving viloxazine ER were determined. C<sub>max</sub> was 1.60 ± 0.70 μg/mL at 100 mg, 2.83 ± 1.31 μg/mL at 200 mg, and 5.61 ± 2.48 μg/mL at 400 mg. AUC<sub>0-t</sub> was 19.29 ± 8.88 μg·h/mL at 100 mg, 34.72 ± 16.53 μg·h/mL at 200 mg, and 68.00 ± 28.51 μg·h/mL at 400 mg. PK parameters for adolescents receiving viloxazine ER were also determined. C<sub>max</sub> was 2.06 ± 0.90 μg/mL at 200 mg, 4.08 ± 1.67 μg/mL at 400 mg, and 6.49 ± 2.87 μg/mL at 600 mg. AUC<sub>0-t</sub> was 25.78 ± 11.55 μg·h/mL at 200 mg, 50.80 ± 19.76 μg·h/mL at 400 mg, and 79.97 ± 36.91 μg·h/mL at 600 mg. Simulations revealed that, regardless of the duration of the dosing interruption, viloxazine concentration returned to steady-state levels after approximately 2 days of once-daily dosing of viloxazine ER.</AbstractText>
          <CopyrightInformation>© 2021 Supernus Pharmaceuticals, Inc. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nasser</LastName>
            <ForeName>Azmi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gomeni</LastName>
            <ForeName>Roberto</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacometrica, Lieu-dit Longcol, La Fouillade, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhao</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kosheleff</LastName>
            <ForeName>Alisa R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Lanyi</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adeojo</LastName>
            <ForeName>Lilian W</ForeName>
            <Initials>LW</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schwabe</LastName>
            <ForeName>Stefan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Clin Pharmacol</MedlineTA>
        <NlmUniqueID>0366372</NlmUniqueID>
        <ISSNLinking>0091-2700</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018759">Adrenergic Uptake Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5I5Y2789ZF</RegistryNumber>
          <NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018759" MajorTopicYN="N">Adrenergic Uptake Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008657" MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009010" MajorTopicYN="N">Monte Carlo Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014745" MajorTopicYN="N">Viloxazine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">ADHD</Keyword>
        <Keyword MajorTopicYN="Y">SPN-812</Keyword>
        <Keyword MajorTopicYN="Y">drug holiday</Keyword>
        <Keyword MajorTopicYN="Y">pharmacokinetics</Keyword>
        <Keyword MajorTopicYN="Y">population PK</Keyword>
        <Keyword MajorTopicYN="Y">viloxazine</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>16</Day>
          <Hour>8</Hour>
          <Minute>55</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34269426</ArticleId>
        <ArticleId IdType="doi">10.1002/jcph.1940</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Yu C, Garcia-Olivares J, Candler S, et al. New insights into the mechanism of action of viloxazine: Serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285-300.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. A phase 3, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended release) in the treatment of ADHD in school-age children. Clin Ther. 2020;42(8):1452-1466.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2021;41(4):370-380.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021;43(4):684-700.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharm Bul. 2021;51(2):43-64.</Citation>
        </Reference>
        <Reference>
          <Citation>Findling RL, Candler S, Nasser A, et al. Viloxazine in the management of CNS disorders: a historical overview and current status. CNS Drugs. 2021;35(6):643-653.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Kosheleff AR, Hull JT, et al. Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention deficit/hyperactivity disorder. Int J Clin Pract. 2021;75(8):e14330.</Citation>
        </Reference>
        <Reference>
          <Citation>Adli M, Baethge C, Heinz A, et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? Eur Arch Psychiatryclin Neurosci. 2005;255(6):387-400.</Citation>
        </Reference>
        <Reference>
          <Citation>Berney P. Dose-response relationship of recent antidepressants in the short-term treatment of depression. Dialogn Clin Neurosci. 2005;7(3):249.</Citation>
        </Reference>
        <Reference>
          <Citation>Yu C. Metabolism and in vitro drug-drug interaction assessment of viloxazine. Xenobiotica. 2020;50(11):1285-1300.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Z, Kosheleff AR, Adeojo L, et al. Impact of paroxetine, a strong CYP2D6 inhibitor, on SPN-812 (viloxazine extended-release) pharmacokinetics in healthy adults. Clin Pharmacol Drug Develop. 2021; doi: 10.1002/cpdd.948.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Z, Adeojo LW, Odebo O, et al. Impact of SPN-812 (Viloxazine Extended-Release) on Select Cytochrome P450 (CYP) Activity and the Evaluation of CYP2D6 Polymorphisms on SPN-812 Pharmacokinetics. Abstract presented at: Society of Biological Psychiatry 2021; Annual Meeting; (Virtual).</Citation>
        </Reference>
        <Reference>
          <Citation>Aarons L. Population pharmacokinetics: theory and practice. Brit J Clin Pharmacol. 1991;32(6):669.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Faison SL, Liranso T, et al. Evaluation of the effect of SPN-812 (viloxazine extended release) on QTc interval in healthy adults. J Clin Psychiatry. 2020;81(6):e1-e6.</Citation>
        </Reference>
        <Reference>
          <Citation>Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of co-administered viloxazine extended-release (SPN-812) and methylphenidate in healthy adults. Clin Drug Invest. 2020;41(2):149-159.</Citation>
        </Reference>
        <Reference>
          <Citation>Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of co-administered viloxazine extended-release (SPN-812) and lisdexamfetamine in healthy adults. J Clin Psychopharm. 2021;41(2):155-162.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Hull JT, Liranso T, et al. The Effect of viloxazine extended-release capsules on functional impairments associated with attention-deficit/hyperactivity disorder (ADHD) in children and adolescents in four phase 3 placebo-controlled trials. Neuropsychiatr Dis Treat. 2021;17:1751-1762.</Citation>
        </Reference>
        <Reference>
          <Citation>Vandel B, Vandel S, Jounet J, Blum D. Pharmacokinetics of viloxazine hydrochloride in man. Eur J Drug Metab Pharmacokinet. 1982;7(1):65-68.</Citation>
        </Reference>
        <Reference>
          <Citation>Evans ND, Godfrey KR, Chapman MJ, Chappell MJ, Aarons L, Duffull SB. An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine. J Pharmacokinet Pharmacodynam. 2001;28(1):93-105.</Citation>
        </Reference>
        <Reference>
          <Citation>Qelbree (Viloxazine Extended-Release Capsules) [prescribing information]. Rockville, MD: Supernus Pharmaceuticals, Inc.; 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharmaceut Res. 1998;15(9):1463-1468.</Citation>
        </Reference>
        <Reference>
          <Citation>R: A language and environment for statistical computing [computer program]. R Foundation for Statistical Computing; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEN user's guides (1989-2020). Ellicott City, MD: Icon Development Solutions; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241-257.</Citation>
        </Reference>
        <Reference>
          <Citation>Pisani F, Fazio A, Spina E, et al. Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. Psychopharmacology. 1986;90(3):295-298.</Citation>
        </Reference>
        <Reference>
          <Citation>Shyu Y-C, Lee S-Y, Yuan S-S, et al. Seasonal patterns of medications for treating attention-deficit/hyperactivity disorder: comparison of methylphenidate and atomoxetine. Clin Ther. 2016;38(3):595-602.</Citation>
        </Reference>
        <Reference>
          <Citation>Ibrahim K, Vogt C, Donyai P. Caught in the eye of the storm: a qualitative study of views and experiences of planned drug holidays from methylphenidate in child and adolescent ADHD treatment. Child Adolesc Ment Health. 2016;21(4):192-200.</Citation>
        </Reference>
        <Reference>
          <Citation>Ibrahim K, Donyai P. Drug holidays from ADHD medication: international experience over the past four decades. J Attention Dis. 2015;19(7):551-568.</Citation>
        </Reference>
        <Reference>
          <Citation>Boissel J-P, Nony P. Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor compliance. Clin Pharmacokinet. 2002;41(1):1-6.</Citation>
        </Reference>
        <Reference>
          <Citation>Osterberg L, Urquhart J, Blaschke T. Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther. 2010;88(4):457-459.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34269426</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1552-4604</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>61</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical pharmacology</Title>
          <ISOAbbreviation>J Clin Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Population Pharmacokinetics of Viloxazine Extended-Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder.</ArticleTitle>
        <Pagination>
          <StartPage>1626</StartPage>
          <EndPage>1637</EndPage>
          <MedlinePgn>1626-1637</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jcph.1940</ELocationID>
        <Abstract>
          <AbstractText>Viloxazine extended-release capsules (viloxazine ER; Qelbree) is a novel nonstimulant, recently approved by the US Food and Drug Administration for the treatment of ADHD in pediatrics. Here, we characterize the pharmacokinetics (PK) of viloxazine and its major metabolite, 5-HVLX-gluc, using a population PK model and evaluate the impact of 1-4 days of missed viloxazine ER doses on viloxazine PK. Data from 4 phase 3 trials in pediatric subjects treated with viloxazine ER were used to establish the PK model. Covariate analysis was conducted on the final base model. The impact of 1-4 days of missed doses on steady-state viloxazine PK was evaluated using Monte Carlo simulations. A 1-compartmental linear model with first-order absorption and elimination of the parent drug and first-order metabolite formation and elimination properly described the population PK of viloxazine and 5-HVLX-gluc. Body weight impacted the systemic exposure of viloxazine and 5-HVLX-gluc. Predicted PK parameters at steady state (mean ± standard deviation) in children receiving viloxazine ER were determined. C<sub>max</sub> was 1.60 ± 0.70 μg/mL at 100 mg, 2.83 ± 1.31 μg/mL at 200 mg, and 5.61 ± 2.48 μg/mL at 400 mg. AUC<sub>0-t</sub> was 19.29 ± 8.88 μg·h/mL at 100 mg, 34.72 ± 16.53 μg·h/mL at 200 mg, and 68.00 ± 28.51 μg·h/mL at 400 mg. PK parameters for adolescents receiving viloxazine ER were also determined. C<sub>max</sub> was 2.06 ± 0.90 μg/mL at 200 mg, 4.08 ± 1.67 μg/mL at 400 mg, and 6.49 ± 2.87 μg/mL at 600 mg. AUC<sub>0-t</sub> was 25.78 ± 11.55 μg·h/mL at 200 mg, 50.80 ± 19.76 μg·h/mL at 400 mg, and 79.97 ± 36.91 μg·h/mL at 600 mg. Simulations revealed that, regardless of the duration of the dosing interruption, viloxazine concentration returned to steady-state levels after approximately 2 days of once-daily dosing of viloxazine ER.</AbstractText>
          <CopyrightInformation>© 2021 Supernus Pharmaceuticals, Inc. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nasser</LastName>
            <ForeName>Azmi</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gomeni</LastName>
            <ForeName>Roberto</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacometrica, Lieu-dit Longcol, La Fouillade, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zhao</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kosheleff</LastName>
            <ForeName>Alisa R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xie</LastName>
            <ForeName>Lanyi</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adeojo</LastName>
            <ForeName>Lilian W</ForeName>
            <Initials>LW</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schwabe</LastName>
            <ForeName>Stefan</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Supernus Pharmaceuticals Inc., Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>J Clin Pharmacol</MedlineTA>
        <NlmUniqueID>0366372</NlmUniqueID>
        <ISSNLinking>0091-2700</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018759">Adrenergic Uptake Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5I5Y2789ZF</RegistryNumber>
          <NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018759" MajorTopicYN="N">Adrenergic Uptake Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008657" MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009010" MajorTopicYN="N">Monte Carlo Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014745" MajorTopicYN="N">Viloxazine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">ADHD</Keyword>
        <Keyword MajorTopicYN="Y">SPN-812</Keyword>
        <Keyword MajorTopicYN="Y">drug holiday</Keyword>
        <Keyword MajorTopicYN="Y">pharmacokinetics</Keyword>
        <Keyword MajorTopicYN="Y">population PK</Keyword>
        <Keyword MajorTopicYN="Y">viloxazine</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>16</Day>
          <Hour>8</Hour>
          <Minute>55</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34269426</ArticleId>
        <ArticleId IdType="doi">10.1002/jcph.1940</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Yu C, Garcia-Olivares J, Candler S, et al. New insights into the mechanism of action of viloxazine: Serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285-300.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. A phase 3, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended release) in the treatment of ADHD in school-age children. Clin Ther. 2020;42(8):1452-1466.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2021;41(4):370-380.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021;43(4):684-700.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Liranso T, Adewole T, et al. A phase 3 placebo-controlled trial of once-daily 400-mg and 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD. Psychopharm Bul. 2021;51(2):43-64.</Citation>
        </Reference>
        <Reference>
          <Citation>Findling RL, Candler S, Nasser A, et al. Viloxazine in the management of CNS disorders: a historical overview and current status. CNS Drugs. 2021;35(6):643-653.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Kosheleff AR, Hull JT, et al. Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention deficit/hyperactivity disorder. Int J Clin Pract. 2021;75(8):e14330.</Citation>
        </Reference>
        <Reference>
          <Citation>Adli M, Baethge C, Heinz A, et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? Eur Arch Psychiatryclin Neurosci. 2005;255(6):387-400.</Citation>
        </Reference>
        <Reference>
          <Citation>Berney P. Dose-response relationship of recent antidepressants in the short-term treatment of depression. Dialogn Clin Neurosci. 2005;7(3):249.</Citation>
        </Reference>
        <Reference>
          <Citation>Yu C. Metabolism and in vitro drug-drug interaction assessment of viloxazine. Xenobiotica. 2020;50(11):1285-1300.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Z, Kosheleff AR, Adeojo L, et al. Impact of paroxetine, a strong CYP2D6 inhibitor, on SPN-812 (viloxazine extended-release) pharmacokinetics in healthy adults. Clin Pharmacol Drug Develop. 2021; doi: 10.1002/cpdd.948.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang Z, Adeojo LW, Odebo O, et al. Impact of SPN-812 (Viloxazine Extended-Release) on Select Cytochrome P450 (CYP) Activity and the Evaluation of CYP2D6 Polymorphisms on SPN-812 Pharmacokinetics. Abstract presented at: Society of Biological Psychiatry 2021; Annual Meeting; (Virtual).</Citation>
        </Reference>
        <Reference>
          <Citation>Aarons L. Population pharmacokinetics: theory and practice. Brit J Clin Pharmacol. 1991;32(6):669.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Faison SL, Liranso T, et al. Evaluation of the effect of SPN-812 (viloxazine extended release) on QTc interval in healthy adults. J Clin Psychiatry. 2020;81(6):e1-e6.</Citation>
        </Reference>
        <Reference>
          <Citation>Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of co-administered viloxazine extended-release (SPN-812) and methylphenidate in healthy adults. Clin Drug Invest. 2020;41(2):149-159.</Citation>
        </Reference>
        <Reference>
          <Citation>Faison SL, Fry N, Adewole T, et al. Pharmacokinetics of co-administered viloxazine extended-release (SPN-812) and lisdexamfetamine in healthy adults. J Clin Psychopharm. 2021;41(2):155-162.</Citation>
        </Reference>
        <Reference>
          <Citation>Nasser A, Hull JT, Liranso T, et al. The Effect of viloxazine extended-release capsules on functional impairments associated with attention-deficit/hyperactivity disorder (ADHD) in children and adolescents in four phase 3 placebo-controlled trials. Neuropsychiatr Dis Treat. 2021;17:1751-1762.</Citation>
        </Reference>
        <Reference>
          <Citation>Vandel B, Vandel S, Jounet J, Blum D. Pharmacokinetics of viloxazine hydrochloride in man. Eur J Drug Metab Pharmacokinet. 1982;7(1):65-68.</Citation>
        </Reference>
        <Reference>
          <Citation>Evans ND, Godfrey KR, Chapman MJ, Chappell MJ, Aarons L, Duffull SB. An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine. J Pharmacokinet Pharmacodynam. 2001;28(1):93-105.</Citation>
        </Reference>
        <Reference>
          <Citation>Qelbree (Viloxazine Extended-Release Capsules) [prescribing information]. Rockville, MD: Supernus Pharmaceuticals, Inc.; 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharmaceut Res. 1998;15(9):1463-1468.</Citation>
        </Reference>
        <Reference>
          <Citation>R: A language and environment for statistical computing [computer program]. R Foundation for Statistical Computing; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEN user's guides (1989-2020). Ellicott City, MD: Icon Development Solutions; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241-257.</Citation>
        </Reference>
        <Reference>
          <Citation>Pisani F, Fazio A, Spina E, et al. Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. Psychopharmacology. 1986;90(3):295-298.</Citation>
        </Reference>
        <Reference>
          <Citation>Shyu Y-C, Lee S-Y, Yuan S-S, et al. Seasonal patterns of medications for treating attention-deficit/hyperactivity disorder: comparison of methylphenidate and atomoxetine. Clin Ther. 2016;38(3):595-602.</Citation>
        </Reference>
        <Reference>
          <Citation>Ibrahim K, Vogt C, Donyai P. Caught in the eye of the storm: a qualitative study of views and experiences of planned drug holidays from methylphenidate in child and adolescent ADHD treatment. Child Adolesc Ment Health. 2016;21(4):192-200.</Citation>
        </Reference>
        <Reference>
          <Citation>Ibrahim K, Donyai P. Drug holidays from ADHD medication: international experience over the past four decades. J Attention Dis. 2015;19(7):551-568.</Citation>
        </Reference>
        <Reference>
          <Citation>Boissel J-P, Nony P. Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor compliance. Clin Pharmacokinet. 2002;41(1):1-6.</Citation>
        </Reference>
        <Reference>
          <Citation>Osterberg L, Urquhart J, Blaschke T. Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther. 2010;88(4):457-459.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
